Las Vegas, NV -- (SBWIRE) -- 12/17/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Solta Medical Inc (NASDAQ:SLTM), NuPathe Inc (NASDAQ:PATH), CytRx Corporation (NASDAQ:CYTR), Agenus Inc (NASDAQ:AGEN)
Solta Medical Inc (NASDAQ:SLTM) managed to keep its gain at 39.71% on above-normal volume of 28.33M shares. The stock settled at $2.92 after floating in a range of $2.91 to $2.95. Its latest price has reached market capitalization of $235.76 million. Its 52-week range has been $1.44 to $2.95. Solta Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets energy-based medical device systems for aesthetic applications primarily in North America, the Asia Pacific, Europe, and the Middle East. It offers Fraxel re:pair system for use in dermatological procedures requiring ablation, coagulation, and resurfacing of soft tissue, as well as for rhytides, pigmentation, dyschromia, fine lines, acne, surgical scars, deeper lines, wrinkles, and actinic keratoses; and Clear + Brilliant system, a treatment to improve skin texture and help prevent the signs of aging skin.
For How Long SLTM will fight for Profitability? Read This Trend Analysis report
NuPathe Inc (NASDAQ:PATH) traded up on a volume of 10.65 million, higher than its standard daily volume. Shares have gained 47.39% to $3.39. Over the last twelve months, the stock has gained 6.1% and faced a worst price of $1.57. NuPathe Inc., a specialty pharmaceutical company, focuses on the development and commercialization of branded therapeutics for neurological and psychiatric disorders.
For How Long PATH’s Gloss will Attract Investors? Find out via this report
CytRx Corporation (NASDAQ:CYTR) settled -8.74% lower at $5.22 on above-normal volume of 9.66M shares during the last trading day. The stock has its 12-month high at $6.79 and 52-week low price was $1.80. It traded in a range of $4.92 to $5.78 during the last trading day. CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes two programs, aldoxorubicin and tamibarotene, which are in clinical development for cancer indications. The aldoxorubicin is in pivotal Phase 3 preparation ongoing stage of development for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy.
Will CYTR Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Agenus Inc (NASDAQ:AGEN) was up on high volume, trading at a volume of 9.58M versus its average daily volume of 260,580.00 shares. At $2.75, the stock has attained market capitalization of 97.55 million. Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies.
Will AGEN Continue To Move Higher? Find Out Here
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)